SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
Salix Pharmaceuticals, Ltd.
---------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
794906 3 05
------------------------
(CUSIP Numbers)
December 31, 1999
-----------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
- ------------------------
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
____________________________________________________________
1. Name of Reporting Person
I.R.S. Identification No. of Above Person
John F. Chappell
____________________________________________________________
2. Check the Appropriate Box if a Member of a Group
(See Instructions)
(a) ____
Not Applicable (b) ____
____________________________________________________________
3. SEC Use Only
____________________________________________________________
4. Citizenship or Place of Organization
United States
____________________________________________________________
5. Sole Voting Power
Number of 909,494
Shares ________________________________________
Beneficially 6. Shared Voting Power
Owned By
Each Reporting
Person ________________________________________
7. Sole Dispositive Power
909,494
________________________________________
8. Shared Dispositive Power
____________________________________________________________
9. Aggregate Amount Beneficially Owned by Each
Reporting Person
909,494
____________________________________________________________
<PAGE>
10. Check if the Aggregate Amount in Row (9) Excludes
Certain Shares (See Instructions)
/ /
____________________________________________________________
11. Percent of Class Represented by Amount in Row (9)
8.91%
____________________________________________________________
12. Type of Reporting Person (See Instructions)
IN
____________________________________________________________
<PAGE>
ITEM 1(A) NAME OF ISSUER
Salix Pharmaceuticals, Ltd.
ITEM 1(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
3600 W. Bayshore Road, Suite 205, Palo Alto, CA 94303
ITEM 2(A) NAME OF PERSON FILING
John F. Chappell
ITEM 2(B) ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE
1787 Sentry Parkway West, Bldg. 16, Suite 350, Blue Bell, PA, 19422
ITEM 2(C) CITIZENSHIP
United States
ITEM 2(D) TITLE OF CLASS OF SECURITIES
Common Stock
ITEM 2(E) CUSIP NUMBER
794906 3 05
ITEM 3. FILING PURSUANT TO RULES 13D-1(B) OR 13D-2(B)
Not Applicable
ITEM 4. OWNERSHIP
(a) Amount beneficially owned: 909,494
(b) Percent of class:
8.91%
<PAGE>
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 909,494
(ii) Shared power to vote or to direct the vote:
(iii) Sole power to dispose or to direct the disposition of: 909,494
(iv) Shared power to dispose or to direct the disposition of:
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not Applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable
ITEM 10. CERTIFICATION
Not Applicable
<PAGE>
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 14, 2000
- --------------------------------------------
Date
/s/ John F. Chappell
- --------------------------------------------
John F. Chappell
